Helena A. Yu, MD
Thoracic Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Lung Cancer
- Targeted Therapies for Lung Cancer
- Clinical Trials
Request an Appointment
About Me
- Associate Attending Physician
I am a board-certified medical oncologist specializing in the care of patients with lung cancer. As a member of our multidisciplinary team that includes surgeons and radiation oncologists, I am dedicated to providing compassionate care to my patients and creating comprehensive treatment plans that are tailored to their needs and goals.
Read more
By performing molecular testing on lung cancers, we have the ability to look for specific gene mutations and personalize the treatment for each patient based on the results of these tests. I have a special interest in the use and development of newer, targeted therapies as treatment for lung cancers.
I also conduct research aimed at advancing the treatment of lung cancer so that patients can live longer and have a better quality of life. My clinical research focuses on the treatment of patients with lung cancers that have identifiable mutations, and I oversee our clinical research program for patients with EGFR-mutant lung cancers.
A thoracic medical oncologist is a cancer doctor who specializes in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Lung Cancer
- Targeted Therapies for Lung Cancer
- Clinical Trials
Education
- MD, University of Michigan Medical School
Residencies
- Internal Medicine - Hospital of the University of Pennsylvania
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Yu sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Yu
- A Phase 1 Study of AZD9592 Alone and With Other Treatments in People With Solid Tumors
- A Phase 2 Study of Zipalertinib in People With Advanced Non-Small Cell Lung Cancer
- A Phase I Study of BDTX-1535 in People with Advanced Non-Small Cell Lung Cancer
- A Phase I/IIA Study of CLN-081 in People with Non-Small Cell Lung Cancer
Read more
- A Phase II Study of Osimertinib Alone or with Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers Who Have Detectable Tumor DNA in the Blood After Starting Osimertinib
- A Phase III Study of Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Non-Small Cell Lung Cancer
- Clinical Trials Co-Investigated by Dr. Yu
- A Phase 2 Study of Targeted Treatment for MET Exon 14 Skipping-Positive Advanced Non-Small Cell Lung Cancer
- A Phase I Study of BCA101, Alone and Combined with Pembrolizumab Immunotherapy, in People with Advanced Lung Cancer
- A Phase I Study of Deferoxamine in People with Leptomeningeal Metastasis
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Yu’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Helena A. Yu discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Black Diamond Therapeutics, Inc.
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
C4 Therapeutics
Professional Services and Activities
-
Daiichi Sankyo
Professional Services and Activities -
Ipsen Pharma
Professional Services and Activities -
Janssen Pharmaceuticals, Inc.
Professional Services and Activities -
Taiho
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].